XML 46 R34.htm IDEA: XBRL DOCUMENT v2.4.0.6
COMMITMENTS AND CONTINGENCIES (Details) (USD $)
In Millions, unless otherwise specified
 1 Months Ended 6 Months Ended 1 Months Ended 6 Months Ended 1 Months Ended
Apr. 30, 2011
Daiichi Sankyo
Jun. 30, 2012
Daiichi Sankyo
Jul. 31, 2011
Daiichi Sankyo
Minimum
country
Jun. 30, 2012
Daiichi Sankyo
Minimum
Jun. 30, 2012
Daiichi Sankyo
Maximum
Oct. 31, 2007
ALIGN
product
Aug. 31, 2012
Sinclair
Subsequent event
Aug. 10, 2012
Sinclair
Minimum
Subsequent event
Licensing Agreements                
Up-front fee and certain past reimbursements $ 1.6              
Future milestone payments payable   10.0            
Period for which royalties will be paid following the first commercial sale of licensed products in the country   10 years            
Notice period for termination of license by the entity for technical, scientific, efficacy, safety, or commercial reasons   6 months            
Notice period for termination of license after launch of a sapacitabine-based product by the entity, or by either party for material default   12 months            
Number of countries for which regulatory approval is required by September 2011 to sell sapacitabine as per termination right waived after amendment to the agreement     1          
Percentage of increase in royalty due on future net sales of sapacitabine after amendment       1.25% 1.50%      
Number of products for which exclusive rights acquired to sell and distribute products           3    
Quarterly installments receivable under royalty arrangement               $ 1.0
Period of royalty arrangement             3 years